Anteris Technologies Global Corp. — Interim / Quarterly Report 2008

Apr 10, 2008

Innovative BioMedical Devices

bioMD Limited ABN 35 088 221 078

==> picture [50 x 38] intentionally omitted <==

Level 11, 225 St Georges Terrace, Perth Telephone (08) 9262 6777 Western Australia 6000 Facsimile (08) 9322 3433 PO Box 7209, Cloisters Square www.biomd.co Western Australia 6850

ANNOUNCEMENT TO THE AUSTRALIAN STOCK EXCHANGE

1 of 7 pages

11 April 2008

Company Announcements Office Australian Stock Exchange Limited 10[th] Floor, 20 Bond Street SYDNEY NSW 2000

Dear Sir/Madam,

Re: Appendix 4C - Quarterly Report

Enclosed please find the quarterly report for the period ended 31 March 2008 for the Company.

Please refer to the ‘Appendix 4C’ attached for details.

Yours faithfully,

==> picture [80 x 60] intentionally omitted <==

Caroline L Bentley Company Secretary

Rule 4.7B

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of entity
bioMD Limited
ABN 36 088 221 078	Quarter ended (“current quarter”)
36 088 221 078	31 March 2008

Consolidated statement of cash flows

Cash flows related to operating activities 1.1 Receipts from customers 1.2 Payments for (a) staff costs (b) advertising and marketing (c) research and development (d) leased assets (e) other working capital 1.3 Dividends received 1.4 Interest and other items of a similar nature received 1.5 Interest and other costs of finance paid 1.6 Income taxes paid 1.7 Other - ATO refunds Net operating cash flows	Current quarter $A’000	Year to date (9 months) $A’000
	- (15) - (33) - (341) - 32 - - 54	- (44) - (248) - (993) - 69 - - 334
	(303)	(882)

	Current quarter $A’000	Year to date (9 months) $A’000
1.8 Net operating cash flows (carried forward)	(303)	(882)
Cash flows related to investing activities 1.9 Payment for acquisition of: (a) businesses (item 5) (b) equity investments (c) intellectual property (d) physical non-current assets (e) other non-current assets 1.10 Proceeds from disposal of: (a) businesses (item 5) (b) equity investments (c) intellectual property (d) physical non-current assets (e) other non-current assets 1.11 Loans to other entities 1.12 Loans repaid by other entities 1.13 Other (provide details if material) Net investing cash flows 1.14 Total operating and investing cash flows	- - - - - - - - - - - - -	- - - (5) - - - - - - - - -
	-	(5)
	(303)	(887)
Cash flows related to financing activities 1.15 Proceeds from issues of shares, options, etc. 1.16 Proceeds from sale of forfeited shares 1.17 Proceeds from borrowings 1.18 Repayment of borrowings 1.19 Dividends paid 1.20 Other - option issue costs Net financing cash flows	- - - - - -	320 - - - - -
	-	320
Net increase (decrease) in cash held 1.21 Cash at beginning of quarter/year to date 1.22 Exchange rate adjustments to item 1.20 1.23 Cash at end of quarter	(303) 1,883 -	(567) 2,147 -
	1,580	1,580

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

1.24 1.25	Aggregate amount of payments to the parties included in item 1.2 Aggregate amount of loans to the parties included in item 1.11	Current quarter $A'000
		146
		-
1.26	Explanation necessaryfor an understandingof the transactions
	Consultancy services and superannuation contributions.

Non-cash financing and investing activities

• 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

• 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

3.1 Loan facilities 3.2 Credit standby arrangements	Amount available $A’000	Amount used $A’000
	-	-
	-	-

Reconciliation of cash

Reconciliation of cash
Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter $A’000	Previous quarter $A’000
4.1 Cash on hand and at bank 4.2 Deposits at call 4.3 Bank overdraft 4.4 Other (provide details)	639	672
	941	1,211
	-	-
	-	-
Total: cash at end of quarter(item 1.23)	1,580	1,883

Acquisitions and disposals of business entities

5.1 Name of entity 5.2 Place of incorporation or registration 5.3 Consideration for acquisition or disposal 5.4 Total net assets 5.5 Nature of business	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))

Compliance statement

• 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.

• 2 This statement does ~~/does not*~~ (delete one) give a true and fair view of the matters disclosed.

Sign here: ............................................................ Date: .......11 April 2008 (Company Secretary) Print name: .........Caroline L Bentley................................................

QUARTERLY REPORT BioMedical Devices and Technologies 3 MONTHS ENDED 31 March 2008

==> picture [141 x 74] intentionally omitted <==

11 April 2008

==> picture [96 x 292] intentionally omitted <==

QUARTER HIGHLIGHTS

•  First production batch of CardioCel Bioimplant Tissue patches completed;

•  CardioCel Bioimplant Tissue Patches exported to South Africa to commence Phase II human clinical trial;

• CardioCel included on Australian Register of Therapeutic Goods (ARTG);

 Research & Development

• In vivo bovine peritoneum 6 months trial completed;

• Kangaroo tail tendons 6 months pre-clinical trial completed;

• Acquisition of global research report for the soft tissue repair markets in both United States of America and Europe.

==> picture [289 x 32] intentionally omitted <==

==> picture [289 x 32] intentionally omitted <==

==> picture [289 x 32] intentionally omitted <==

==> picture [289 x 31] intentionally omitted <==

==> picture [135 x 7] intentionally omitted <==

----- Start of picture text -----

bioMD Limited ABN 35 088 221 078
----- End of picture text -----

==> picture [289 x 5] intentionally omitted <==

PO Box 7209 Cloisters Square WA 6850 • Tel +61 8 9262 6777 • Fax +61 8 9322 3433 E-mail: info@biomd.com.au • Web Site: www.biomd.com.au

QUARTERLY REPORT ON ACTIVITIES 3 months ended 31 March 2008

bioMD LIMITED

QUARTERLy REVIEW

During the quarter the Company successfully completed its first production batch of CardioCel.

==> picture [171 x 123] intentionally omitted <==

CardioCel

CardioCel is a bioimplant tissue patch made from bovine pericardium tissue and treated with ADAPT[®] Tissue Processing Technology (TPT), the company’s proprietary technology.

==> picture [98 x 104] intentionally omitted <==

In total, 38 units of CardioCel were produced at Cell and Tissue Therapies WA, Royal Perth Hospital. This is the first consignment to South Africa for the commencement of our Phase II human clinical trial.

Ethics Approval has been received for the human clinical trial with an initial enrolment number of 50 patients.

The second production batch is expected to be completed during the current quarter.

RESEARCH & DEVELOPMENT

In Vivo Bovine Peritoneum Trial

In vivo research into the crosslink stability of bovine peritoneum was completed with the bovine peritoneum being explanted at 6 months.

==> picture [112 x 91] intentionally omitted <==

The explanted bovine peritoneum showed evidence of of host cells and newly formed capillaries, well distributed within the tissue.

Results from the trial confirmed the ability of ADAPT treated peritoneum tissue to remodel into host tissue where there is a functional demand for the tissue.

The peritoneum tissue provides larger patch sizes suitable for large ventral hernia repair.

Pre-clinical Animal Trial of Kangaroo Tail Tendons

The pre-clinical animal trial using kangaroo tail tendons in a rat model was to assess the calcification levels of this tendon tissue when used in orthopaedic joint surgery. It was completed at 6 months.

==> picture [114 x 97] intentionally omitted <==

The explanted tendon treated with ADAPT TPT was flooded with host fibroblasts and there was evidence of prominent new vascularisation inside the matrix.

There were no signs of calcification. Indications are that these tendons could be used as an “off the shelf” ACL repair ligament.

REGULATORy

CardioCel has been included as a Class I (Export Only) Medical Device on the Australian Register of Therapeutic Goods with the ARTG No. 150536.

Work has continued on the implementation of a Quality Management System to ISO13485, which sets out specific requirements for the design, development and manufacture of our bioimplant tissue patches.

CORPORATE OVERVIEW

• bioMD’s market capitalisation at the end of the reported period was $7.6 million, based on a closing price of 9.1 cents.

•  The consolidated group has $1.68 million in cash reserves and an average burn rate of $100K per month for the 3 months to 31 March 2008.

bioMD Limited ABN 35 088 221 078 PO Box 7209 Cloisters Square WA 6850 • Tel +61 8 9262 6777 • Fax +61 8 9322 3433 E-mail: info@biomd.com.au • Web Site: www.biomd.com.au